Remune™
ONS in oncology

I'm a Healthcare Professional - please accept

This website is an international information resource intended only for Healthcare Professionals. By clicking “Confirm” you are declaring and confirming that you are a Healthcare Professional and have read and understood this disclaimer.

Confirm Cancel

Remune™ – Your partner in the nutritional management of oncological patients

Remune peach and raspberry
Remune™ is a key product in nutrition therapy of cancer patients.

Product description

Remune™ is a partially balanced Food for Special Medical Purposes (FSMP) for the dietary management of disease-related malnutrition in patients with pre-cachexia or cachexia especially due to cancer or COPD and for patients undergoing chemotherapy.

Remune™ is a supplement to be used in addition to normal food or in combination with standard oral nutrition supplements (ONS).

Remune™ aims to increase the intake of polyunsaturated omega-3 fatty acids from fish oil and vitamin D3 together with energy and protein in order to supply patients with sufficient amounts of nutrients which they may not get through their normal diet. Remune™ is not suitable as the sole source of nutrition.

Why Remune™?

You are looking for a tasty supplement in compliance with the ESPEN and ASPEN guidelines for nutrition in oncology? Remune™ has a smoothie-like texture and is very tasty. 

Moreover, it contains EPA and DHA from low oxidized fish oil to supplement the nutritional needs of cancer patients at risk of malnutrition or with cachexia and pre-cachexia.

A closer look at the content of Remune™ and its benefits

Dosage and Age groups: 2 units / day, unless otherwise specified by a clinician or dietician. Suitable for children > 4 years, adults and elderly.

Drink Remune™ directly out of the container with the provided straw or pour into a glass. Available in raspberry and peach flavor.

Remune flavors
Remune™ in two tasty flavors.

Special features:

  • Partially balanced
  • Fruit-juice-based emulsion (86% fruit content)
  • High content of EPA & DHA from fish oil (2000 mg / pack)
  • High content of vitamin D
  • High biological value whey protein
  • Contains 9.6 g of protein / pack
  • Smoothie-like, fresh and fruity taste
  • Flavors: Peach and Raspberry

Nutritional details of Remune™

Nutritional content Remune
Nutritional details
Remune nutritional content
Remune™ content
Nutritional content Remune
Nutritional details
Remune nutritional content
Remune™ content
Pre-cachexia survival rates
Fig. 1: survival rates with Remune™ in pre-cachectic cancer patients, adapted from Laviano et al.1

Compared to an isocaloric milk-based drink patients nourished with Remune™ showed:

  • Potentially better survival in the subset of patients with pre-cachexia (post-hoc analysis, Fig. 1)
  • No negative effect on tolerability of the platinum-based chemotherapy treatment1
  • Good tolerability – numerical smaller number of adverse events compared to the comparator group (64 vs. 87 AE)1
  • Increased omega-3 fatty acids (EPA and DHA) and vitamin D levels in plasma

Highlights

Description Document Link
Clinical study with Remune™ Laviano et al. Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial
pdf (358.9 KB) open

ONS products in oncology

Have a look at our product range for oral nutrition support. Choose the suitable option for your patient’s needs and taste.

Find the right product

Diagnosing malnutrition

Malnutrition is more than weight loss. There are multiple ways to diagnose it. Find more information on the various tools and diagnostic criteria.

Be aware of the nutrition care process
Nutricomp Drinks

Nutricomp® Drinks

These Drinks can be used as supplementary or complete nutrition with essential nutrients, vitamins and minerals.

Discover Nutricomp®

1 Laviano A, Calder PC, Schols AMWJ, Lonnqvist F, Bech M, Muscaritoli M. Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial. Nutr Cancer. 2020;72(3):439-450.